BACKGROUND: Renal medullary carcinoma is a rare kidney tumor with highly aggressive behavior. This tumor occurs exclusively in young patients with sickle cell trait or disease. To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established. METHODS: The authors analyzed the gene expression profiles of 2 renal medullary carcinomas from patients with sickle cell trait using microarrays containing 21,632 cyclic DNA (cDNA) clones and compared them with the gene expression profiles of 64 renal tumors. RESULTS: Based on global gene clustering with 3583 selected cDNAs, the authors found a distinct molecular signature of renal medullary carcinoma, which clustered closely with urothelial (transitional cell) carcinoma of the renal pelvis, rather than renal cell carcinoma (RCC). This finding of a significant difference in the gene expression patterns of renal medullary carcinoma compared with RCC suggests that this tumor should not be treated as a conventional RCC but, rather, as a special malignancy. This study also identified genes/proteins that may serve as biomarkers for renal medullary carcinoma or as potential targets of novel therapies. In addition, comparative genomic microarray analysis allowed the authors to predict the lack of chromosomal imbalances in this tumor. CONCLUSIONS: To the authors' knowledge, the current study is the first molecular profiling of renal medullary carcinoma, a rare but highly aggressive kidney carcinoma. The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions. Copyright 2004 American Cancer Society.
BACKGROUND:Renal medullary carcinoma is a rare kidney tumor with highly aggressive behavior. This tumor occurs exclusively in young patients with sickle cell trait or disease. To the authors' knowledge, very little is known to date regarding the underlying molecular genetics of this tumor, and no effective therapy has been established. METHODS: The authors analyzed the gene expression profiles of 2 renal medullary carcinomas from patients with sickle cell trait using microarrays containing 21,632 cyclic DNA (cDNA) clones and compared them with the gene expression profiles of 64 renal tumors. RESULTS: Based on global gene clustering with 3583 selected cDNAs, the authors found a distinct molecular signature of renal medullary carcinoma, which clustered closely with urothelial (transitional cell) carcinoma of the renal pelvis, rather than renal cell carcinoma (RCC). This finding of a significant difference in the gene expression patterns of renal medullary carcinoma compared with RCC suggests that this tumor should not be treated as a conventional RCC but, rather, as a special malignancy. This study also identified genes/proteins that may serve as biomarkers for renal medullary carcinoma or as potential targets of novel therapies. In addition, comparative genomic microarray analysis allowed the authors to predict the lack of chromosomal imbalances in this tumor. CONCLUSIONS: To the authors' knowledge, the current study is the first molecular profiling of renal medullary carcinoma, a rare but highly aggressive kidney carcinoma. The genes that are expressed specifically in this tumor may lead to not only a better understanding of its molecular pathways and discoveries of novel diagnostic markers but also, more important, to effective therapeutic interventions. Copyright 2004 American Cancer Society.
Authors: Erin M Goodwin; Qing Zhong; Catherine S Abendroth; Lindsay K Ward-Kavanagh; Todd D Schell; Timothy K Cooper Journal: Comp Med Date: 2013-08 Impact factor: 0.982
Authors: Peter H O'Donnell; Ana Jensen; Edwin M Posadas; Julia A Bridge; Anjana V Yeldandi; Ximing J Yang; Walter M Stadler; Hikmat Al-Ahmadie Journal: Nat Rev Urol Date: 2010-02 Impact factor: 14.432
Authors: Amishi Y Shah; Jose A Karam; Gabriel G Malouf; Priya Rao; Zita D Lim; Eric Jonasch; Lianchun Xiao; Jianjun Gao; Ulka N Vaishampayan; Daniel Y Heng; Elizabeth R Plimack; Elizabeth A Guancial; Chunkit Fung; Stefanie R Lowas; Pheroze Tamboli; Kanishka Sircar; Surena F Matin; W Kimryn Rathmell; Christopher G Wood; Nizar M Tannir Journal: BJU Int Date: 2016-12-09 Impact factor: 5.588
Authors: Roula Albadine; Wenle Wang; Noel A Brownlee; Antoun Toubaji; Athanase Billis; Perdram Argani; Jonathan I Epstein; A Julian Garvin; Rima Cousi; Edward M Schaeffer; Christian Pavlovich; George J Netto Journal: J Urol Date: 2009-06-18 Impact factor: 7.450
Authors: Nathaniel E Smith; Andrea T Deyrup; Adrian Mariño-Enriquez; Jonathan A Fletcher; Julia A Bridge; Peter B Illei; George J Netto; Pedram Argani Journal: Am J Surg Pathol Date: 2014-06 Impact factor: 6.394
Authors: Jacob S Lipkin; Syed M Rizvi; Zoran Gatalica; Nabeel E Sarwani; Sheldon L Holder; Mathew Kaag; Joseph J Drabick; Monika Joshi Journal: Cancer Biol Ther Date: 2015 Impact factor: 4.742
Authors: Ali Imran Amjad; Hira Ali; Leonard J Appleman; Jodi Maranchie; Stephen Jackman; Anil Parwani; Rajiv Dhir; Somak Roy; Rahul A Parikh Journal: Case Rep Oncol Med Date: 2014-08-19